Daniel Sem, Ph.D., MBA, JD is vice provost for research and innovation, as well as a professor of business and of pharmaceutical sciences at Concordia University Wisconsin. He is also the CEO of both Bridge to Cures, Inc. and Retham Technologies, co-founder and vice president for business development of Estrigenix Therapeutics and serves as director of the Remedium eXchange (Rx) Think Tank.
Sem received his bachelor’s degree in chemistry from the University of Wisconsin-Milwaukee, his Ph.D. in biochemistry from the University of Wisconsin-Madison and his Juris Doctor and Master of Business Administration degrees from Marquette University.
- New Wisconsin bill directly solves the problem with growing healthcare costs
- Innovators stifled by current healthcare system